
Key Points
- The EPO revoked EP 3773494 on October 13, publishing the decision on November 17.
- Another Philip Morris nicotine pouch patent, EP 3809884, was revoked on September 24; both proceedings involved challenges from BAT entities.
- EP 3809884 covers a pouch membrane containing at least 15% of the product's total nicotine, while EP 3773494 addresses free-base nicotine, ion-exchange resin and a minimum 15% water content.
- Both patents were revoked after Philip Morris withdrew its approval of the patent texts. The boards did not issue final substantive findings that the claimed technologies lacked novelty or inventive step.
- The patents share a June 7, 2019 priority basis. Related European filings include EP 4108105 and EP 4079290.
2Firsts
November 18, 2026
The European Patent Office (EPO) has revoked a European nicotine pouch formulation patent held by Philip Morris International (PMI), marking the second such patent owned by the tobacco group to be revoked in less than a month following challenges from British American Tobacco (BAT) entities.
The latest decision, published on November 17, concerns EP 3773494, a patent covering a formulation involving free-base nicotine, ion-exchange resin and elevated moisture content.
In September, the EPO revoked another Philip Morris patent, EP 3809884, covering the distribution of nicotine between the material inside a pouch and its outer membrane.
In both appeals, Philip Morris withdrew its approval of the patent text. The EPO revoked the patents under Article 113(2) of the European Patent Convention without reaching a final substantive determination on the patentability of the claimed inventions.
Nicoventures Appeals Amended Patent, PMI Withdraws Approval of Text
The latest patent, EP 3773494, is titled "Nicotine Pouch Composition and Pouch Comprising Such."
Its European application was filed on June 5, 2020, and the patent was granted on April 6, 2022.
Public patent records identify Danish company NCP Nextgen AS as the original applicant, with ownership later registered to Philip Morris Products S.A.
In 2023, BAT entity Nicoventures Trading Limited filed an opposition against the patent.
During opposition proceedings, Philip Morris submitted amended patent claims. In December 2024, the EPO Opposition Division decided to maintain the patent in amended form.
Nicoventures appealed, challenging the decision to allow the amendments and maintain the patent.
According to the EPO appeal record and a November 17 report by British legal publication Law360, Philip Morris initially sought dismissal of the appeal but subsequently withdrew its approval of the patent text during oral proceedings.
Article 113(2) of the European Patent Convention requires the EPO to examine and decide upon a European patent only in a text submitted or agreed to by the patent proprietor.
With the proprietor no longer approving the text on which the patent could be maintained, the Board of Appeal set aside the earlier decision and revoked the patent.
The case is T 0263/25. The decision was issued on October 13 and published on November 17.
EP 3773494: Free-Base Nicotine, Ion-Exchange Resin and High-Moisture Formulation
EP 3773494 concerns the composition of the material inside an oral nicotine pouch.
Its principal granted claim specifies free-base nicotine mixed with ion-exchange resin at a weight ratio of free-base nicotine to resin between 0.1 and 2.0. The composition must also contain at least 15% water by weight.
The patent describes possible use of polacrilex resin, plant-based fibers, sugar alcohols and pH-regulating ingredients.
According to the patent specification, combining free-base nicotine with different carrier materials may influence nicotine-release characteristics. Elevated moisture content may also affect the interaction between the pouch composition and saliva and contribute to the product's perceived mouthfeel.
These effects are described in the patent specification as part of the proposed technology.
The patent's principal technical subject matter concerns the pouch's internal formulation, including nicotine form, resin ratios and water content.
EP 3809884: Earlier Patent Covering Nicotine Distribution in Pouch Membrane
Before the latest decision, the EPO Board of Appeal revoked another Philip Morris nicotine pouch patent, EP 3809884, on September 24. The decision was published on September 30.
That patent, titled "Nicotine Pouch Product," was granted on September 21, 2022.
Unlike EP 3773494, which principally addresses the internal formulation, EP 3809884 concerns the distribution of nicotine between the pouch's internal composition and its outer membrane.
Its principal granted claim requires the pouch composition to contain at least one water-insoluble fiber, at least 15% water by weight and nicotine. The pouch membrane must contain additional nicotine representing at least 15% of the total nicotine content of the product.
The specification describes a mechanism in which nicotine located in the outer membrane can be released during the initial period of use, in addition to nicotine released from the material inside the pouch.
The patent also discusses membrane materials and manufacturing methods, including applying nicotine to the membrane or transferring nicotine into it under specified processing conditions.
British-American Tobacco (Investments) Limited was the opponent in the proceedings concerning EP 3809884.
The EPO's decision in case T 0057/25 records that Philip Morris withdrew its approval of the patent text, leading the Board of Appeal to revoke the patent.
The two cases can be compared as follows:
| Item | EP 3809884 | EP 3773494 |
|---|---|---|
| Appeal | T 0057/25 | T 0263/25 |
| Technology | Nicotine distribution and release through pouch membrane | Free-base nicotine, resin and moisture content |
| Key quantitative requirements | At least 15% of total nicotine in membrane; at least 15% water in internal composition | Nicotine-to-resin weight ratio of 0.1–2.0; at least 15% water |
| Opponent | British-American Tobacco (Investments) Limited | Nicoventures Trading Limited |
| Decision date | September 24, 2026 | October 13, 2026 |
| Publication date | September 30, 2026 | November 17, 2026 |
| Outcome | Revoked | Revoked |
Both revocations followed the patent proprietor's withdrawal of approval of the patent text. The EPO did not make final findings in these decisions that the inventions lacked novelty or inventive step.
Patents Share Priority Basis, With Related European Divisional Applications
Public patent records show that EP 3809884 and EP 3773494 share a Danish priority application dated June 7, 2019, and identify the same inventors.
The two patents originate from different European and international PCT applications, with distinct technical claims and subject matter.
Other related European applications are recorded within the respective filing chains.
EP 4108105 B1 is a divisional patent stemming from the application associated with EP 3809884. It was granted on June 4, 2025. EP 4552511 is another divisional record within the same application chain.
For the formulation technology, EP 4079290 is a divisional application associated with EP 3773494. Its published claims concern nicotine pouch compositions and related products.
Each divisional filing is subject to its own examination, claims and legal status. The scope of any remaining protection for related technology depends on the enforceable claims and status of those separate applications and patents.
Some public patent databases still display EP 3809884 and EP 3773494 as active, despite the EPO's more recent appeal decisions. The EPO's published revocation decisions provide the authoritative record of the outcomes in the two cases.
ZYN–VELO Competition Extends to Nicotine Pouch Intellectual Property
PMI and BAT are major competitors in the global modern oral nicotine market.
PMI acquired the ZYN brand and related businesses through its 2022 acquisition of Swedish Match. BAT competes through its VELO brand in the United States, Europe and other markets.
Both groups maintain intellectual property portfolios covering nicotine pouch formulations, materials, manufacturing processes and nicotine-release technologies.
The two European patent revocations involved different BAT entities, while the proprietor in both cases was Philip Morris Products S.A.
The published decisions did not establish whether the claimed inventions were used in specific commercial ZYN or VELO products, nor did they find that any marketed product infringed the patents.
Law360 reported that representatives for Philip Morris and BAT did not immediately respond to requests for comment on the latest decision. Publicly available materials reviewed for this report do not explain Philip Morris's commercial reasons for withdrawing approval of the patent texts in the two proceedings.
Follow 2Firsts for developments in nicotine pouch technology, intellectual property disputes and competition among international tobacco companies.
Cover Image generated by AI











